Sushil Suri Proven Great Contributor of Revenue for Morepen Laboratory


Mr. Sushil Suri, science alumna and Chartered Accountant joined Morepen’s Board of Directors from last 10 years. Mr. Sushil Suri has been the cornerstone in the success story of the Morepen Laboratories. At Morepan he is also involved in the day-to-day activities of production, product planning and operations etc. The future growth model of the company will mainly focus on the formulations. Earlier the company was more into bulk drugs. Traditionally all the big brothers started as bulk companies and they slowly turned to formulations. Five years down the line 75% of our sales will be coming from formulations and OTC, whereas 25% of the sales will come from bulk drugs.
In formulations our major focus will be on the life style categories. Primarily in the categories of Neuro pschycriatic, cardiac and chest and diabetes where we are launching new products. Another segment that is very popular is gynecology. Gynae is not a new segment. India is the largest producer of kids in the world. So it happens to be a big segment. Gynae of late was never considered as a priority because India was always having unhygienic conditions. Whereas we are very much focused on a niche model. We have got high profitability but today we are not getting very high multiples. MorepenSushil Suri strategy is very clear, we track the patents and the moment the patent expires we are there first and if we are not first we won’t be there.

We have got US approvals and are the only generic company to get approvals so far. The moment patent expires we will be getting good returns and profits. Sushil Suri CBI hope that whatever money we have invested will be recovered in 2 to 3 years. The incubation period is over and we are waiting for the returns. We do have some more alliances in pipeline. We are working on similar lines bringing in foreign partners using our distribution muscle. And the new area what we would be adding is OTC also. May be some products related to the consumers like home diagnostics etc. We have already planned for the last seven years and are still investing on FDA approvals, etc. So the moment loratidine goes off patent we are sitting on a block of assets. We do not have any immediate expansion plans.

Comments

Popular posts from this blog

Sushil Suri The Only Name Behind The Success Of Morepen

Sushil Suri Help to Increase the Brand Value of Dr. Morepen

Rise of Morepen by Dr. Sushil Suri